Table 2 Patient demographics, disease parameters, and baseline biomarker serum concentrations from MOBILITY part B biomarker analysis
Placebo + MTX (n = 128) | Sarilumab 200 mg q2w + MTX (n = 131) | Totala (n = 259) | |
|---|---|---|---|
Baseline demographic and disease parameters | |||
Age, mean ± SD, years | 51.1 ± 10.6 | 49.3 ± 12.3 | 50.2 ± 11.5 |
Sex, female, % | 77.3 | 84.7 | 81.1 |
Duration of RA, mean ± SD, years | 9.1 ± 8.2 | 8.1 ± 6.7 | 8.6 ± 7.5 |
Anti-CCP antibody positive, % | 82.8 | 87.0 | 84.9 |
Rheumatoid factor positive, % | 87.5 | 87.8 | 87.6 |
Tender joint count, mean ± SD | 27.3 ± 14.8 | 25.9 ± 14.5 | 26.6 ± 14.7 |
Swollen joint count, mean ± SD | 15.8 ± 8.0 | 16.6 ± 10.6 | 16.2 ± 9.4 |
CRP, mean ± SD, mg/dL | 1.7 ± 1.9 | 2.1 ± 2.1 | 1.9 ± 2.0 |
mTSS, mean ± SD | 51.8 ± 72.1 | 45.9 ± 60.2 | 48.8 ± 66.3 |
Baseline biomarker serum concentrations, median (quartile 1/quartile 3) | |||
C1M, ng/mL | 114.0 (77.0/175.7) | 120.5 (86.1/196.3) | 119.6 (80.7/184.2) |
C2M, ng/mL | 0.3 (0.2/0.4) | 0.3 (0.2/0.4) | 0.3 (0.2/0.4) |
C3M, ng/mL | 43.1 (34.6/58.0) | 45.4 (34.4/60.5) | 44.2 (34.5/59.9) |
CTX-1, ng/mL | 0.4 (0.3/0.6) | 0.4 (0.3/0.5) | 0.4 (0.3/0.5) |
MMP-3, ng/mL | 41.9 (24.6/77.6) | 38.9 (21.3/68.7) | 40.3 (22.3/73.1) |
OC, ng/mL | 18.3 (13.0/25.0) | 18.6 (14.6/24.7) | 18.5 (13.5/24.7) |
OPG, pmol/L | 4.9 (3.9/6.3) | 5.4 (3.9/6.7) | 5.2 (3.9/6.5) |
sRANKL, pmol/L | 1012.5 (385.0/3893.0) | 1096.0 (393.0/2161.5) | 1026.0 (387.0/2748.5) |
sRANKL/OPG | 245.1 (64.4/836.5) | 186.3 (71.8/401.2) | 212.6 (70.8/509.7) |